Filing summary
Entity mismatch: The request identifies Skye Bioscience, Inc., but the supplied Form 10-Q is for Load Guard Logistics, Inc. This summary reflects the filing provided, not Skye Bioscience.
Business context and reporting period
Load Guard Logistics is a development-stage transportation and logistics company based in Miami, Florida. It earns revenue from freight transportation and arranging transportation through others. The unaudited report covers the quarter and six months ended April 30, 2013; its fiscal year ends October 31. Operations began in October 2012, so the prior-year revenue comparison is not meaningful.
Financial performance and position
| Metric | Three months ended April 30, 2013 | Six months ended April 30, 2013 |
|---|---|---|
| Revenue | $108,929 | $166,059 |
| Operating income (loss) | $3,612 | ($2,582) |
| Net income | $2,069 | $2,229 |
| Operating margin | 3.3% | (1.6%) |
| Net margin | 1.9% | 1.3% |
| Operating cash flow | ($13,950) for six months |
Six-month revenue comprised $146,810 of direct trucking revenue, $13,532 of brokerage income, and $5,717 of fuel surcharges. Fuel costs were 41% of trucking revenue for the six months; wages were 27% and operations and maintenance were 18.9%, according to management.
At April 30, cash was $29,712; accounts receivable were $32,078; total current assets were $64,897; and current liabilities were $52,929. Working capital was $11,968, down from $34,023 at October 31, 2012. The current ratio was approximately 1.23. Total liabilities were $68,780, including $57,000 of related-party note principal. Equipment, net, was $69,471.
Six-month investing cash outflow was $64,542, principally reflecting $74,116 of equipment purchases, partly offset by collections on a related-party note. Financing provided $81,800, including $24,800 from stock issuance and $57,000 from related-party notes. Cash increased $3,308 during the period.
Changes, outlook, risks, and unusual items
- Compared with the prior-year periods, revenue increased from zero as operations commenced in October 2012. The company reported six-month net income versus a $202 loss in the comparable 2012 period.
- The company disclosed substantial doubt about its ability to continue as a going concern. It reported operating cash outflow, development-stage operations, and a possible need for further financing. Management plans to seek public or private equity funding and may seek loans from officers or directors; success is not assured and equity funding could dilute shareholders.
- Management’s liquidity statements conflict: one passage says cash and operating income should cover continuing operations for the next 12 months, while another says cash on hand is insufficient to cover operating costs for that period. Officer funding is described as verbal and unenforceable, with no specific commitment.
- Management cited competitive freight-broker pricing and fuel costs as pressure on operating economics. Fuel surcharges recover a majority of fuel increases, but continued recovery is not assured. The company planned to use offering proceeds to expand its fleet and hire drivers.
- Related-party financing included an 8% note and an unsecured, non-interest-bearing $25,000 note for a tractor and trailer. The filing also describes potential conflicts involving officers and directors and no formal policy for resolving them.
- Management identified material weaknesses in financial reporting controls, including no functioning audit committee, insufficient independent board oversight, inadequate segregation of duties, and management concentration. It said these weaknesses could lead to a material misstatement in future periods.
- The company reported no material legal proceedings or defaults on senior securities. It changed its independent auditor on June 14, 2013, after the quarter end.
Key investor verification points
- Confirm the intended issuer: the supplied filing is for Load Guard Logistics, not Skye Bioscience.
- Reconcile the filing’s conflicting descriptions of whether available liquidity can fund operations for 12 months, and verify the status and terms of any financing or officer advances.
- Review the six-month net income discrepancy: the financial statements report $2,229, while one MD&A table appears to show $202.
- Verify the related-party debt balances, repayment terms, and use of proceeds from the equity offering.
- Assess progress in addressing the disclosed material weaknesses and the implications of the auditor change.